Grouping Multiple Change Applications in Tanzania
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Tanzania permits several changes to be combined into one application, but the rules tighten layer by layer. TMDA/DMD/MDA/G/003 §6.1 organises the possibilities as follows.
| Layer | Rule | Provision |
|---|---|---|
| Multiple changes within one product (§6.1.1) | Major, minor and notifiable changes may be combined into one change application, provided they are submitted together. Fees and assessment are charged at the highest change category in the application | §6.1.1 |
| Identical changes affecting several approved products (§6.1.2) | One application may be submitted for: (i) identical administrative changes to several approved products; (ii) addition of the same new product to several approved products (submitted together). Non-identical changes mixed into any one listing may result in the entire application being unaccepted | §6.1.2(a) |
| Same device appearing in several registrations (§6.1.2(b)) | Where the same device appears in several registrations as part of a family, system, group or test kit, one change application may be submitted; the selected products on which the change is implemented must be identical across the registered family/system/group/kit | §6.1.2(b) |
| Identical changes across risk classes (§6.1.3) | Only 4 categories may be combined into one application | §6.1.3 |
The 4 categories of §6.1.3: a) a change of the product applicant/marketing authorisation holder; b) a change of manufacturing and/or sterilisation site; c) a change involving only the update of the validity of the QMS certificate; d) the addition of an identical Class A accessory.
The architecture is deliberately restrictive: consolidation is a cost-saving tool for administrative content, not a general bundling mechanism. Anything that touches the technical substance of the product is expected to stand on its own application, and misjudging this boundary can cost an entire submission rather than just a fee surcharge.
2. Legal basis
| Instrument | Reference | Publication date | Provisions |
|---|---|---|---|
| Guidelines on Submission of Application for Change(s) to Approved Medical Devices and In-Vitro Diagnostics | TMDA/DMD/MDA/G/003, Rev. 00, First Edition | June 2022 | §6.1.1, §6.1.2(a)(b)(c), §6.1.3(a)–(d), §6.2 |
| The Tanzania Medicines and Medical Devices (Fees and Charges) Regulations, 2022 | Fees Regulations (2022) | 2022 | Major variation: medical devices 300 USD / IVD 500 USD; Minor variation: medical devices 150 USD / IVD 200 USD |
| Compendium of Guidelines for Marketing Authorization of Medical Devices, Diagnostics and Laboratory Equipment | No Government Gazette number (TMDA guideline document) | June 2024 | Part IX (grouping: family/system/group/test kit/cluster) |
3. Expert insights
Insight 1: The highest-category charging rule of §6.1.1 is a cost-control rule.
Where one submission contains a major change together with minor and notifiable changes, fees and assessment are charged at the highest category present, namely major. This means that bundling several minor or notifiable changes with one major change prices the cheap changes at the major rate as well. Conversely, separating the major change into its own application and submitting the remainder as minor or notifiable changes is more cost-efficient. GRZAN’s practice is to calculate the classification first and only then decide whether consolidation pays.
Insight 2: The rule that non-identical changes cause the entire application to be unaccepted is the harshest provision in the section.
The original text reads: “Non-identical changes in any one listing may result in the entire application for changes being unaccepted.” Note the word entire. Stuffing twenty products with twenty different changes into one application in the name of efficiency means that a single non-identical item can sink the whole submission. This is a high-penalty rule, and the identical nature of each change must be verified line by line before filing.
Insight 3: §6.1.2 opens only two doors: identical administrative changes and adding the same new product to several registrations.
Beyond these, §6.1.2(c) provides that non-identical changes not falling into the listed categories must be submitted as separate applications for each change. The consolidation space in Tanzania is therefore genuinely narrow – what can be combined is essentially administrative content, such as contact details or certificate updates, and technical changes must be filed individually even where they are conceptually similar.
Insight 4: §6.1.3 compresses cross-risk-class consolidation to 4 categories, two of which concern system documentation.
Of the 4 categories, holder changes (a) and site changes (b) belong to the certificate-information type, while the QMS certificate validity update (c) and the addition of an identical Class A accessory (d) belong to the low-risk supplementation type. What the four share is that none of them changes the technical content of the product. Any change involving technical content cannot be consolidated across risk classes, whatever its apparent similarity.
Insight 5: Consolidated applications and recall-triggered changes follow different procedures.
§6.2 requires recall-triggered changes to be brought to TMDA’s attention before submission, while the consolidation rules of §6.1 carry no such pre-step. Where both apply to the same submission – for example a consolidated application that includes a recall-triggered change – the stricter procedure prevails, so the pre-submission contact must be made even though the application as a whole was filed under §6.1.
4. Practical recommendations
- Calculate the classification before deciding to consolidate – under §6.1.1 the highest category governs the fee, so bundling does not always save money.
- Define identical administrative changes strictly: changes across products must be literally identical; one mixed item endangers the whole application (§6.1.2(a)).
- Submit technical changes per product; do not force them into a consolidated application (§6.1.2(c)).
- Use only the 4 consolidation channels across risk classes (§6.1.3): holder change, site change, QMS validity update, addition of an identical Class A accessory.
- For changes to the same device within a family/system/group/kit, confirm that the selected implementation products are identical (§6.1.2(b)).
- Where a consolidated application contains a recall-triggered change, contact TMDA first (§6.2).
5. Verification checklist
- □ The fee category of the consolidated application has been calculated under §6.1.1 (highest category governs).
- □ Multi-product consolidation has been confirmed as an identical administrative change or an addition of the same new product (§6.1.2(a)).
- □ No non-identical change has been mixed into any listing (avoiding the entire application being unaccepted).
- □ For changes within a family/system/group/kit, the implementation products have been confirmed as identical (§6.1.2(b)).
- □ Cross-risk-class consolidation falls within one of the 4 categories (§6.1.3).
- □ Where recall-triggered changes are included, TMDA was contacted before submission (§6.2).
Regulatory information verified as of 29 October 2026. All provisions cited in this document were checked against the official texts published by TMDA (TMDA/DMD/MDA/G/003 §6.1.1, §6.1.2, §6.1.3, §6.2; the TMDA website fee schedule; the June 2024 Compendium, Part IX); the review is repeated whenever the regulations are updated.
- Tanzania local resources: GRZAN can coordinate licensed local responsible person (LRP) and distributor resources covering online submission, sample delivery, quality audit support and port release.
- Service capabilities: classification determination, registration and listing pathway selection, preparation and localisation of technical documentation (CSDT/STED), GMDN and grouping strategy, clinical evidence organisation, software and AI device submissions, change management, vigilance and PMS reporting, annual retention fee and renewal management.
- Contact: hito.lin@grzan.cn; website www.grzan.cn.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us